"Amsacrine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects.
Concept/Terms
Amsacrine- Amsacrine
- Cain's Acridine
- Acridine, Cain's
- Cain Acridine
- Cains Acridine
- meta-AMSA
- meta AMSA
- AMSA
- m-AMSA
Amsidyl- Amsidyl
- Gödecke Brand of Amsacrine
- Amsacrine Gödecke Brand
Amsidine- Amsidine
- Parke Davis Brand of Amsacrine Lactate
- Parke Davis Brand of Amsacrine
- AMSA P-D
- AMSA P D
- AMSA PD
- Amsacrina
Below are MeSH descriptors whose meaning is more general than "Amsacrine".
Below are MeSH descriptors whose meaning is more specific than "Amsacrine".
This graph shows the total number of publications written about "Amsacrine" by people in Harvard Catalyst Profiles by year, and whether "Amsacrine" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
2015 | 1 | 0 | 1 |
2016 | 0 | 1 | 1 |
2020 | 1 | 0 | 1 |
Below are the most recent publications written about "Amsacrine" by people in Profiles.
-
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. J Clin Oncol. 2021 03 01; 39(7):768-778.
-
Combination chemotherapy of solid tumors: an American-Italian collaboration: a celebration of the work of Gianni Bonadonna. Tumori. 2016 Mar-Apr; 102(2):124-6.
-
A synthetic lethal approach for compound and target identification in Staphylococcus aureus. Nat Chem Biol. 2016 Jan; 12(1):40-5.
-
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen. Biol Blood Marrow Transplant. 2012 Mar; 18(3):466-72.
-
Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia. Bone Marrow Transplant. 2009 Dec; 44(12):785-92.
-
Regression supports two mechanisms of fork processing in phage T4. Proc Natl Acad Sci U S A. 2008 May 13; 105(19):6852-7.
-
Random mutagenesis of the B'A' core domain of yeast DNA topoisomerase II and large-scale screens of mutants resistant to the anticancer drug etoposide. Biochem Biophys Res Commun. 2005 Feb 11; 327(2):597-603.
-
Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol. 1997 Nov; 15(11):3378-87.
-
Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study. J Clin Oncol. 1996 May; 14(5):1521-5.
-
Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide. Leukemia. 1992 Jun; 6(6):582-7.